In arrivo numerose assunzioni Novartis in Campania. La casa farmaceutica amplierà lo stabilimento di Torre Annunziata (Napoli ...

«È un momento cruciale per migliorare il nostro approccio alle cure», afferma Dennis Slamon, oncologo attivo sul tema, in ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Three years after launching Leqvio in the U.S., Novartis is still steadily advancing its blockbuster ambitions for the cholesterol-lowering drug. Early Wednesday, the company touted phase 3 ...

Aug 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab said on Saturday it had received a binding offer from Germany's Siemens Healthineers (SHLG.DE), opens new tab to acquire its ...

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million ...

Novartis confirmed that it has received a binding offer from Siemens Healthineers to buy its molecular imaging business for an undisclosed amount. The Swiss pharma major said Monday that the ...

Novartis has partnered with Versant Ventures to establish Borealis Biosciences, a Canada-based independent, discovery-stage biotech company. The collaboration has resulted in $150m Series A ...